A Tyr Pharma Inc LIFE
We take great care to ensure that the data presented and summarized in this overview for aTYR PHARMA INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding LIFE
View all-
Federated Hermes, Inc. Pittsburgh, PA14.7MShares$27.3 Million0.06% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct4.88MShares$9.08 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.6MShares$6.71 Million0.0% of portfolio
-
Tikvah Management LLC Charlotte, NC2.46MShares$4.58 Million1.33% of portfolio
-
Woodline Partners LP San Francisco, CA1.68MShares$3.13 Million0.02% of portfolio
-
Black Rock Inc. New York, NY1.39MShares$2.59 Million0.0% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL1.28MShares$2.38 Million0.01% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA1MShares$1.86 Million0.0% of portfolio
-
Logos Global Management LP San Francisco, CA1MShares$1.86 Million0.24% of portfolio
-
Octagon Capital Advisors LP New York, NY900KShares$1.67 Million0.37% of portfolio
Latest Institutional Activity in LIFE
Top Purchases
Top Sells
About LIFE
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. It is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.
Insider Transactions at LIFE
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 04
2025
|
Nancy Denyes General Counsel |
SELL
Open market or private sale
|
Direct |
899
-3.27%
|
$2,697
$3.78 P/Share
|
|
Feb 04
2025
|
Jill Marie Broadfoot Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,254
-3.8%
|
$3,762
$3.78 P/Share
|
|
Feb 03
2025
|
Sanjay Shukla President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,375
+6.6%
|
-
|
|
Feb 03
2025
|
Nancy Denyes General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
2,687
+8.91%
|
-
|
|
Feb 03
2025
|
Jill Marie Broadfoot Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+10.2%
|
-
|
|
Jul 24
2024
|
Paul Schimmel |
BUY
Open market or private purchase
|
Indirect |
52,300
+11.24%
|
$52,300
$1.93 P/Share
|
|
Jul 23
2024
|
Paul Schimmel |
BUY
Open market or private purchase
|
Indirect |
6,648
+1.81%
|
$6,648
$1.82 P/Share
|
|
Jul 22
2024
|
Paul Schimmel |
BUY
Open market or private purchase
|
Indirect |
41,052
+10.39%
|
$41,052
$1.74 P/Share
|
|
Jun 05
2024
|
Nancy Denyes General Counsel |
BUY
Open market or private purchase
|
Direct |
5,000
+18.34%
|
$5,000
$1.86 P/Share
|
|
May 31
2024
|
Jill Marie Broadfoot Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+15.17%
|
$5,000
$1.79 P/Share
|
|
May 31
2024
|
Sanjay Shukla President and CEO |
BUY
Open market or private purchase
|
Direct |
20,000
+12.78%
|
$20,000
$1.81 P/Share
|
|
May 30
2024
|
Timothy Coughlin |
BUY
Open market or private purchase
|
Indirect |
50,000
+47.17%
|
$50,000
$1.75 P/Share
|
|
Feb 06
2024
|
Jill Marie Broadfoot Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,590
-7.09%
|
$1,590
$1.69 P/Share
|
|
Feb 05
2024
|
Sanjay Shukla President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,375
+8.17%
|
-
|
|
Feb 05
2024
|
Nancy Denyes General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
2,688
+15.4%
|
-
|
|
Feb 05
2024
|
Jill Marie Broadfoot Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+14.33%
|
-
|
|
Dec 12
2023
|
Sanjay Shukla President and CEO |
BUY
Open market or private purchase
|
Direct |
12,000
+10.15%
|
$12,000
$1.18 P/Share
|
|
Dec 11
2023
|
Sanjay Shukla President and CEO |
BUY
Open market or private purchase
|
Direct |
3,000
+3.09%
|
$3,000
$1.17 P/Share
|
|
Nov 13
2023
|
Sanjay Shukla President and CEO |
BUY
Open market or private purchase
|
Direct |
13,578
+12.96%
|
$13,578
$1.11 P/Share
|
|
Nov 10
2023
|
Sanjay Shukla President and CEO |
BUY
Open market or private purchase
|
Direct |
1,422
+1.8%
|
$1,422
$1.14 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 16.8K shares |
|---|---|
| Open market or private purchase | 180K shares |
| Open market or private sale | 2.15K shares |
|---|